Caren van Roekel

150 Chapter 5 TABLE 3. RECIST 1.1 response classification at 3-months post-treatment (continued) Stable disease 0 (0%) Progressive disease 11 (100%) Holmium-166 No extrahepatic metastases at baseline 11 (46%) Complete response 0 (0%) Partial response 2 (18%) Stable disease 4 (36%) Progressive disease 5 (46%) Extrahepatic metastases at baseline 13 (54%) Complete response 0 (0%) Partial response 0 (0%) Stable disease 1 (8%) Progressive disease 12 (92%) * This table shows a comparison of RECIST 1.1 response classification at three-months post- treatment for patients with or without extrahepatic metastases at baseline. Numbers represent number of patients (% of total/subcategory). * marks significant difference between groups; p<0.05 Prognostic value of extrahepatic disease at baseline based on overall survival (OS) Median OS for the 90 included patients was 10 months (95% CI 9-14 months). Presence of extrahepatic metastases at baseline showed a difference in median OS estimates with ten months (95% CI: 7-14) for patients with-, and 12 months (95% CI: 9-19) for patients without extrahepatic metastases at baseline (hazard ratio (HR) 1.68, 95%CI (1.09-2.59), p=0.019) (Figure 4).